References
- Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjogren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000; 29: 20–8
- Champey J, Corruble E, Gottenberg JE, Buhl C, Meyer T, Caudmont C, et al. Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features. Arthritis Rheum 2006; 55: 451–7
- Fox PC. Autoimmune diseases and Sjögren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci 2007; 1098: 15–21
- Szodoray P, Gal I, Barath S, Aleksza M, Horvath IF, Gergely P, Jr, et al. Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand J Rheumatol 2008; 37: 205–12
- Szodoray P, Alexy P, Brunz JG, Centolay M, Jonsson R. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004; 59: 592–9
- Garcia-Carrasco M, Font J, Filella X, Cervera R, Ramos-Casals M, Sisó A, et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001; 19: 411–15
- Willeke P, Gaubitz M, Schotte H, Becker H, Domschke W, Schlüter B. The role of interleukin-10 promoter polymorphisms in primary Sjögren's syndrome. Scand J Rheumatol 2008; 37: 293–9
- Spath-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998; 83: 1573–9
- Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality-of-life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000; 22: 128–39
- Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002; 61: 554–8
- Alonso J, Prieto L, Antó JM. [The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results], in “Spanish. Med Clin (Barc) 1995; 104: 771–6
- Hartkamp A, Geenen R, Bijl M, Kruize AA, Godaert GLR, Derksen RHWM. Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjögren's syndrome. Ann Rheum Dis 2004; 63: 1335–7
- Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619–26
- De Jongh RF, Vissers KC, Meert TF, Booij LH, De Deyne CS, Heylen RJ. The role of interleukin-6 in nociception and pain. Anesth Analg 2003; 96: 1096–103
- Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004; 361: 184–7